Acute ulcerative colitis animal model and construction method thereof
By reducing or inhibiting TOPK gene expression and drinking sodium glucan sulfate, an animal model of acute colorectitis was constructed, solving the problems of long-term model construction time and mild inflammation in the prior art, and achieving a faster and more severe inflammation model , shortened the experimental cycle.
Patent Information
- Application Number
- CN202411083594.7
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-08
- Publication Date
- 2024-11-19
AI Technical Summary
In the prior art, the model of acute colorectitis in mice has been constructed for a long time and has a mild degree of inflammation, which is difficult to meet research needs.
Animal model of acute colorectitis was constructed by reducing or completely inhibiting the expression and function of TOPK genes in experimental animals and allowing them to drink 1% to 3% sodium dextran sulfate for 4 to 7 days. This method includes gene knockout, gene silencing or the use of PROTAC technology, and specifically uses CRISPR/Cas technology, etc. to ensure that the specific exons of the TOPK gene are not expressed or the expression is inhibited.
It significantly shortens the construction time of animal models of acute colorectitis, increases the severity of inflammation, and thus shortens the cycle of relevant experiments.
Smart Images

Figure CN118979070A_ABST
Abstract
Description
Technical Field
[0001] The invention relates to the technical field of constructing animal models, and in particular to an acute ulcerative colitis animal model and a construction method thereof. Background Art
[0002] Ulcerative colitis is an idiopathic inflammatory disease of the intestinal mucosa, which can manifest as acute diarrhea, abdominal pain, blood in the stool, vomiting and other symptoms. Ulcerative colitis is a recognized precancerous lesion of colorectal cancer, and the duration of inflammation is positively correlated with the risk of canceration. The acute colitis model of mice induced by dextran sulphate sodium (DSS) is similar to the lesions of human ulcerative colitis, and is an ideal animal model for studying the specific pathogenesis of ulcerative colitis and developing treatment methods. In the prior art, in the process of inducing the acute colitis model of mice, there are problems such as long model construction time and mild inflammation. Summary of the invention
[0003] The purpose of the present invention is to provide an acute ulcerative colitis animal model and a construction method thereof, by which the construction time of the acute ulcerative colitis animal model is significantly shortened and the severity is aggravated.
[0004] To this end, in a first aspect, the present invention provides a method for constructing an acute colorectal inflammation animal model, which comprises reducing or completely inhibiting the expression and / or function of the TOPK gene of an experimental animal to obtain a first treated experimental animal; allowing the first treated experimental animal to drink drinking water containing 1% to 3% sodium dextran sulfate for 4 to 7 days, thereby constructing an acute colorectal inflammation animal model.
[0005] In some embodiments, the test animal is selected from at least one of primates (such as humans, monkeys), cattle, sheep, goats, dogs, cats, rabbits, rats, mice, etc.
[0006] In some embodiments, the experimental animal is a rat or a mouse.
[0007] In some embodiments, the experimental animal is a mouse, preferably a C57BL / 6 mouse.
[0008] In some embodiments, the expression and / or function of the TOPK gene of the experimental animal is reduced or completely inhibited by gene knockout, gene silencing, inactivation mutation, PROTAC (targeted protein degradation chimera) technology or small molecule inhibitor treatment.
[0009] In some embodiments, the specific method of gene knockout includes: CRISPR / Cas technology, artificial zinc finger nuclease (Zinc Finger Nucleases, ZFN) technology, transcription activator-like effector (transcriptionactivator-like effector, TALE) technology or TALE-CRISPR / Cas technology.
[0010] In some embodiments, the system used in the CRISPR / Cas technology is selected from CRISPR-Cas3, CRISPR-Cas9, CRISPR-Cas12 (e.g., CRISPR-Cas12a, CRISPR-Cas12b), CRISPR-Cas13 (e.g., CRISPR-Cas13a, CRISPR-Cas13b, CRISPR-Cas13c, CRISPR-Cas13e, CRISPR-Cas13f), CRISPR-CasX, CRISPR-IscB, etc.
[0011] In some embodiments, the specific steps of reducing or completely inhibiting the expression and / or function of the TOPK gene of the experimental animal include: using CRISPR / Cas technology to prevent exon 3 to exon 5 of the TOPK gene from being expressed or inhibiting their expression in the experimental animal, thereby obtaining a first treated experimental animal.
[0012] In some embodiments, the experimental animal is a mouse; a gRNA target is selected and transcribed into RNA in vitro, and injected into a mouse fertilized egg together with a spCas9 (for example, spCas91.1) protein to obtain an F0 generation mouse (founder mouse) with a TOPK gene mutation; the F0 generation mouse is then mated with a wild-type mouse to obtain an F1 generation heterozygous mouse (TOPK+ / -) with a TOPK gene mutation; the F1 generation heterozygous mice (TOPK+ / -) with the same genotype are mated with each other to obtain an F2 generation homozygous mouse (TOPK- / -) with a TOPK gene knockout; the F2 generation homozygous mouse (TOPK- / -), or the mouse derived from mating of the F2 generation homozygous mice (TOPK- / -) is the first treated experimental animal.
[0013] In some embodiments, the first treated experimental animals are made to drink drinking water containing 1% to 3% (w / v) dextran sulfate sodium for 4 to 7 days. Specifically, the concentration of dextran sulfate sodium can be, for example, 1%, 1.5%, 2%, 2.5%, 3%, etc.; the drinking time can be specifically 4 days, 5 days, 6 days or 7 days.
[0014] In some embodiments, the first treated experimental animal is allowed to drink drinking water containing 2% to 3% dextran sulfate sodium for 5 to 7 days;
[0015] In some embodiments, the first treatment experimental animals are allowed to drink drinking water containing 3% dextran sodium sulfate for 2 days, and then drink drinking water containing 2% dextran sodium sulfate for 2 days one day later.
[0016] In some embodiments, the first treatment experimental animals are allowed to drink drinking water containing 2% dextran sodium sulfate for 3 days and drinking drinking water containing 3% dextran sodium sulfate for 2 days.
[0017] In some embodiments, the drinking method is free drinking or oral administration.
[0018] The second aspect of the present invention provides an acute colorectal inflammation animal model, wherein the acute colorectal inflammation animal model is constructed according to the construction method described in the first aspect of the present invention.
[0019] Compared with the prior art, the technical solution of the present invention has the following beneficial effects:
[0020] The present invention provides a method for constructing an animal model of acute colorectal inflammation. By reducing or eliminating the expression of the TOPK gene and / or its biological function, the construction time of the animal model of acute colorectal inflammation is significantly shortened and the severity is aggravated, thereby significantly shortening the cycle of related experiments. BRIEF DESCRIPTION OF THE DRAWINGS
[0021] Various other advantages and benefits will become apparent to those of ordinary skill in the art by reading the detailed description of the preferred embodiments below. The accompanying drawings are only used for the purpose of illustrating the preferred embodiments and are not to be considered as limiting the present invention. In the accompanying drawings:
[0022] Figure 1 : Genotype identification results of wild-type C57BL / 6 mice and TOPK gene-deficient mice;
[0023] Figure 2 :The results of body weight changes of TOPK gene-deficient mice during free drinking of DSS;
[0024] Figure 3 :The weight loss score of TOPK gene-deficient mice during free drinking of DSS;
[0025] Figure 4 :The fecal viscosity score of TOPK gene-deficient mice during free drinking of DSS;
[0026] Figure 5 :Rectal bleeding scores of TOPK gene-deficient mice during free drinking of DSS;
[0027] Figure 6 :Photographs of colorectal tissues of TOPK gene-deficient mice after 7 days of free drinking of DSS;
[0028] Figure 7 : HE staining imaging results of colorectal tissue of TOPK gene-deficient mice after 7 days of free drinking of DSS. DETAILED DESCRIPTION
[0029] The exemplary embodiments of the present disclosure will be described in more detail below with reference to the accompanying drawings. Although the exemplary embodiments of the present disclosure are shown in the accompanying drawings, it should be understood that the present disclosure can be implemented in various forms and should not be limited by the embodiments described herein. On the contrary, these embodiments are provided in order to enable a more thorough understanding of the present disclosure and to fully convey the scope of the present disclosure to those skilled in the art.
[0030] If no specific techniques or conditions are specified in the examples, the experiments were carried out according to conventional techniques or conditions in the art or according to the product instructions. If no manufacturer is specified for the reagents or instruments used, they are all conventional products that can be purchased on the market.
[0031] Example 1 Construction of TOPK gene-deficient mice
[0032] According to the genomic sequence of TOPK (SEQ ID NO: 1), the target and related sequences are designed: According to the current genomic data, there are multiple transcription products of the TOPK gene, among which Exon3-5 is a public exon (the sequences are SEQ ID NO: 2, SEQ ID NO: 3 and SEQ ID NO: 4, respectively). After deleting the Exon 3-5 fragment, the function of the entire gene will be lost. In this embodiment, cas9 targets are designed on both sides of Exon3-5, and approximately 2046bp of the genome are deleted to achieve the knockout of TOPK-201. The candidate target sequences are shown in Table 1, where the underlined ones are PAM sequences.
[0033] Table 1 Candidate target sequences
[0034] name Sequence (5'-3') SEQ ID NO: TOPK-E-F1 AGAAGTCATCTTAGTCAAAGG 5 TOPK-E-F2 TGACTTCTGCAACTCTCATGG 6 TOPK-E-F3 GTGCAGATGTGAATGCTCTGG 7 TOPK-E-R1 GAAATATATACATAACTGAGG 8 TOPK-E-R2 CTCTGCATCCTGCGTGCTGGG 9 TOPK-E-R3 TGTAATGATAGTGATGTTAGG 10
[0035] First, the spCas91.1 / gRNA in vitro enzyme (purchased from Shanghai Huicheng Biotechnology Co., Ltd.) was used to detect the DNA cleavage activity of the above targets. Targets with high activity were selected for subsequent construction of gene mutant mice.
[0036] According to the selected gRNA target with high activity, SEQ ID NO: 14 (AGAAGUCAUCUUAGUCAAAGG) and SEQ ID NO: 15 (CUCUGCAUCCUGCGUGCUGGG) were microinjected into C57BL / 6 mouse fertilized eggs together with spCas91.1 protein (purchased from Shanghai Huicheng Biotechnology Co., Ltd.) to obtain the F0 generation founder mice with gene mutations. The mice were genotyped and the founder mice with the expected mutations were obtained. The genomic DNA was sequenced near the knockout target site to determine that the founder mice carried mutations and fragment deletions occurred.
[0037] The founder mice with mutations were mated with wild-type mice to obtain F1 heterozygous mice with gene mutations (TOPK+ / -), and DNA sequencing was performed to confirm that the TOPK gene was inactivated by fragment deletion, thus achieving gene knockout. F1 heterozygous mice (TOPK+ / -) with the same genotype were mated with each other, and there was a 1 / 4 chance that the F2 mice were homozygous mice with gene knockout. PCR identification yielded F2 homozygous mice with gene knockout (TOPK- / -). Homozygous mice (TOPK- / -) were mated and passed down to obtain the strain of TOPK gene knockout mice.
[0038] In the above steps, the main steps of PCR identification include: clipping the mouse toes, extracting the mouse DNA in a conventional manner after lysis, and using the following identification primers for PCR, wherein the primers M-KO-A49-F and M-KO-A49-R amplify mutant bands, and M-KO-A49-F and M-KO-A49-WT-R amplify wild-type bands:
[0039] M-KO-A49-F: GTGGCTCAGCACAGAATCATAA (SEQ ID NO: 11);
[0040] M-KO-A49-R: AACTTTGAAATGAGAGGCCATT (SEQ ID NO: 12);
[0041] M-KO-A49-WT-R: ATTCCCAGCACATTTATCAGG (SEQ ID NO: 13), the PCR product was separated and detected by agarose gel electrophoresis, and the results were as follows Figure 1 As shown in the figure, the DNA PCR product of TOPK gene-deficient mice is less than 250 bp, while the DNA PCR product of wild-type C57BL / 6 mice is greater than 250 bp, indicating that TOPK gene-deficient mice were successfully constructed.
[0042] The constructed TOPK gene-deficient mice were used in the subsequent examples.
[0043] Example 2
[0044] Eight-week-old mice with similar body weight were selected for the experiment. Wild-type mice (in Figure 2-7 C57BL / 6 or WT) and TOPK gene-deficient mice (in Figure 2-7 The mice were deprived of drinking water for 24 h (as day 0) and then given 2% DSS ad libitum every day.
[0045] The weight of mice was measured and recorded daily, and the statistical results are shown in Figure 2 , weight loss scores are shown in Figure 3 .
[0046] The weight loss scoring criteria are:
[0047] If the weight remains unchanged, it is 0; if the weight loss percentage is 1%-5%, it is 1 point; if the weight loss percentage is 6%-10%, it is 2 points; if the weight loss percentage is 11%-15%, it is 3 points; and if the weight loss percentage is greater than 15%, it is 4 points.
[0048] Observe the mice daily to see if they have sticky stool or bloody stool and record the symptoms. The stool viscosity score is shown in Figure 4 , rectal bleeding score see Figure 5 .
[0049] The scoring criteria for stool consistency are as follows:
[0050] Normal stool (hard, dark brown and granular) is scored as 0 points, loose or mushy stool (unformed soft stool that does not adhere to the perianal area) is scored as 2 points, and watery or egg-drop stool (thin and mushy stool that often adheres to the perianal area) is scored as 4 points.
[0051] Rectal bleeding was scored as follows:
[0052] Normal is 0 points, positive occult blood is 2 points, and overt bleeding is 4 points.
[0053] After 7 days of free drinking of DSS, HE staining imaging of mouse colorectal tissue was performed. The specific steps are as follows:
[0054] (1)Acquisition of materials
[0055] After 7 days of free drinking of DSS, the colorectal tissues of mice were routinely collected and photographed to compare the gross appearance. The photographic results are as follows Figure 6 As shown; the colorectal tissue was rinsed, cut longitudinally, and fixed in 4% paraformaldehyde for 12 h;
[0056] (2) Paraffin embedding
[0057] Dehydration: Immerse the colorectal tissue in liquids in the following order and for the corresponding time: ① 50% ethanol for 1 hour; ② 70% ethanol for 1.5 hours; ③ 85% ethanol for 1 hour; ④ 95% ethanol for 1 hour; ⑤ 100% anhydrous ethanol for 1 hour;
[0058] Transparency: The dehydrated colorectal tissue was immersed in liquids in the following order and for the corresponding time: ① ethanol and xylene mixed in equal proportions for 1 hour; ② xylene (I) for 1 hour; ③ xylene (II) for 1 hour;
[0059] Wax immersion: The colorectal tissue that has been transparentized was immersed in liquid in the following order and for the corresponding time: ① ethanol and xylene mixed in a ratio of 1:1 for 60 minutes; ② xylene for 15 minutes; ③ xylene and paraffin mixed in a ratio of 1:1 for 30 minutes; ④ pure paraffin (I) for 45 minutes; ⑤ pure paraffin (II) for 45 minutes.
[0060] (3) Tissue embedding
[0061] ① After the colorectal tissue is processed according to step (2), prepare the embedding frame in advance, keep the forceps warm (to avoid wax sticking), hold the iron embedding frame in the left hand, and pick up the tissue block with the right hand and put it into the embedding frame;
[0062] ② Place the tissue with the tangent surface facing downward in the embedding box and gently flatten the tissue to prevent bubbles from forming;
[0063] ③ When the wax layer of the paraffin tissue has a thin film, quickly put the wax block in cold water;
[0064] ④ After the wax block is completely solidified, remove the embedding box and repair the wax block. The repair process must be done carefully to prevent the wax block from being damaged, and the wax block tissue is prepared.
[0065] (4) Slicing
[0066] ① Slice the wax block tissue obtained in step (3) using a semi-automatic rotary slicer, with a slice thickness of about 5-6 μm;
[0067] ② After cutting out the slices needed for the experiment, gently lift the slice with the tip of a brush, pick up a corner of the slice with tweezers, and gently lay it flat in constant temperature water at about 45°C with the front side facing up. After the paraffin slices are heated in warm water, they will naturally stretch due to the effect of surface tension. If wrinkles appear, use tweezers to gently unfold them;
[0068] ③ After the slices are fully stretched in the warm water, take them out with a clean glass slide, bake them dry at 60°C, and then place them in a constant temperature oven at 37°C overnight to prepare tissue slices.
[0069] (5) HE staining
[0070] ① Dewaxing and hydration: Soak the tissue sections obtained in step (4) in xylene I, II, and III, respectively, for 2 minutes each time; then soak in anhydrous ethanol I, II, and III, for 1 minute each time; then soak in 95%, 85%, and 75% graded alcohol, for 1 minute each time; finally wash with water for 1 minute;
[0071] ②HE staining: Use hematoxylin to stain the dewaxed and hydrated tissue sections (staining for 8 minutes, staining while observing under a microscope), then extract with hydrochloric acid and alcohol twice, rinse with running water to make it blue, then stain with eosin for 2 seconds, and rinse with running water for 30 seconds;
[0072] ③ Ascending dehydration: soak the HE-stained tissue sections in 85%, 95%, and 100% graded alcohol in sequence for 30 seconds each time;
[0073] ④ Transparent: Soak in I, I, and III layers of xylene in sequence to make it transparent;
[0074] ⑤ Sealing: For tissue sections that have been transparentized, drop neutral gum into the appropriate position of the slide, and slowly cover the slide with a cover glass from one end to prevent bubbles from interfering with later reading. The prepared sections can be dried at room temperature;
[0075] ⑥Observe under the microscope, take pictures, and the imaging results are as follows Figure 7 shown.
[0076] According to the above results, after free drinking of DSS, the weight loss rate, weight loss score, fecal viscosity, and rectal bleeding score of TOPK gene-deficient mice were significantly higher than those of wild-type mice. In addition, the colorectum of TOPK gene-deficient mice was congested, edematous, and shortened. After HE staining, the colorectal tissue structure of TOPK gene-deficient mice was blurred, the gap between the muscular layer and the basal layer was larger, and the degree of inflammation was more serious than that of wild-type mice. The above results show that by applying the technical solution of the present invention, a mouse acute colorectal inflammation model was successfully established.
[0077] Example 3
[0078] Wild-type mice and TOPK gene-deficient mice (TOPK- / -) were routinely raised, and drinking water was stopped for 24 hours (as day 0), and DSS was given to the mice freely according to the treatment method recorded in Table 2 (6 mice in each treatment group), and relevant indicators were tested and counted after the treatment. Among them, the control group was wild-type mice, and the experimental group was TOPK gene-deficient mice.
[0079] The disease activity index (DAI) is a comprehensive score based on weight loss, stool viscosity and rectal bleeding. The weight loss score, stool viscosity score and rectal bleeding score are the same as those in Example 2. The total score of the three results is divided by 3 to obtain the DAI value, that is, DAI = (weight loss score + stool viscosity score + rectal bleeding score) / 3.
[0080] Table 2
[0081]
[0082]
[0083] Note: Compared with control group 1, * P<0.001; compared with experimental group 2, # P<0.05.
[0084] In addition, after the treatment, colorectal HE staining showed that the colon mucosal barrier and glands of mice in control group 1 were intact, the crypt structure was normal, and there was no necrosis, ulcer, inflammatory cell infiltration, submucosal edema, etc.; the colon mucosal defects of mice in experimental group 3 were the most serious, the glands were incomplete, the crypts disappeared, a large number of inflammatory cells infiltrated, the submucosal edema, and the ulcer surface formation was irreversible; experimental groups 2, 4, and 1 were observed to have partial glands, crypts and colon mucosa damaged, inflammatory cell infiltration, submucosal edema, and partial ulcer surface formation, and the case manifestations were alleviated in turn. The above experimental results show that by applying the technical solution of the present invention, the construction time of the animal model of acute colorectal inflammation can be significantly shortened, and its severity can be aggravated, which is conducive to shortening the cycle of related experiments.
[0085] The above is only a preferred specific embodiment of the present invention, but the protection scope of the present invention is not limited thereto. Any changes or substitutions that can be easily thought of by a person skilled in the art within the technical scope disclosed by the present invention should be included in the protection scope of the present invention. Therefore, the protection scope of the present invention shall be based on the protection scope of the claims.
Claims
1. A method for constructing an acute colorectal inflammation animal model, characterized in that: The method comprises reducing or completely inhibiting the expression and / or function of the TOPK gene of the experimental animal to obtain a first treated experimental animal; and making the first treated experimental animal drink drinking water containing 1% to 3% sodium dextran sulfate for 4 to 7 days to construct an acute colorectalitis animal model.
2. The construction method according to claim 1, characterized in that: The test animal is selected from at least one of primates, cattle, sheep, goats, dogs, cats, rabbits, rats, mice, etc.; Preferably, the experimental animal is a rat or a mouse; Preferably, the experimental animal is a C57BL / 6 mouse.
3. The construction method according to claim 1 or 2, characterized in that: The expression and / or function of the TOPK gene of the experimental animal is reduced or completely inhibited by gene knockout, gene silencing, inactivation mutation, PROTAC technology or small molecule inhibitor treatment; Preferably, the specific method of gene knockout includes: CRISPR / Cas technology, artificial zinc finger nuclease technology, transcription activator-like effector technology or TALE-CRISPR / Cas technology.
4. The construction method according to claim 3, characterized in that: The specific steps of reducing or completely inhibiting the expression and / or function of the TOPK gene of the experimental animal include: using CRISPR / Cas technology to prevent the expression of exon 3 to exon 5 of the TOPK gene in the experimental animal or inhibiting the expression, thereby obtaining the first treated experimental animal.
5. The construction method according to claim 4, characterized in that: The experimental animals are mice; the gRNA target is selected and transcribed into RNA in vitro, and injected into mouse fertilized eggs together with the spCas9 protein to obtain F0 generation mice with TOPK gene mutation; the F0 generation mice are then mated with wild-type mice to obtain F1 generation heterozygous mice with TOPK gene mutation; the F1 generation heterozygous mice with the same genotype are mated with each other to obtain F2 generation homozygous mice with TOPK gene knockout; the F2 generation homozygous mice, or the mice derived from mating of the F2 generation homozygous mice, are the first treated experimental animals.
6. The construction method according to any one of claims 1 to 5, characterized in that: The first treatment experimental animals were allowed to drink drinking water containing 2% to 3% dextran sulfate sodium for 5 to 7 days.
7. The construction method according to any one of claims 1 to 5, characterized in that: The first treatment experimental animals were allowed to drink drinking water containing 3% dextran sodium sulfate for 2 days, and then drink drinking water containing 2% dextran sodium sulfate for 2 days after one day.
8. The construction method according to any one of claims 1 to 5, characterized in that: The first treatment experimental animals were allowed to drink drinking water containing 2% dextran sodium sulfate for 3 days and drinking water containing 3% dextran sodium sulfate for 2 days.
9. The construction method according to any one of claims 1 to 8, characterized in that: The drinking method is free drinking or intragastric administration.
10. An animal model of acute colorectal inflammation, characterized in that: The acute colorectal inflammation animal model is constructed according to the construction method described in any one of claims 1-9.
Citation Information
Patent Citations
Method for building dextran sodium sulphate (DSS) induced enteritis mouse model
CN102813671A
Cephradine for prevention and / or treatment of TOPK (T-LAK cell-originated protein kinase) activity abnormally increased skin inflammations by inhibition of TOPK
CN105726545A
Tumor marker and methods of use
US20050064402A1
